Capital Fund Management (CFM)’s TG Therapeutics TGTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.78M	Sell	68,764 -43,920	-39%	-$1.8M	0.02%	1072
2026 Q1	$3.74M	Buy	112,684 +74,530	+195%	+$2.22M	0.02%	1043
2025 Q4	$1.14M	Sell	38,154 -83,467	-69%	-$2.73M	﹤0.01%	1962
2025 Q3	$4.39M	Buy	121,621 +66,899	+122%	+$2.2M	0.01%	1324
2025 Q2	$1.97M	Buy	+54,722	New	+$2.04M	0.01%	1690
2024 Q4	–	Sell	-131,831	Closed	-$3.78M	–	2250
2024 Q3	$3.08M	Sell	131,831 -257,292	-66%	-$5.62M	0.01%	1243
2024 Q2	$6.92M	Buy	389,123 +355,710	+1,065%	+$5.68M	0.02%	824
2024 Q1	$508K	Buy	+33,413	New	+$532K	﹤0.01%	1859
2023 Q4	–	Sell	-80,618	Closed	-$937K	–	2292
2023 Q3	$674K	Buy	+80,618	New	+$1.12M	﹤0.01%	1739
2023 Q1	–	Sell	-52,470	Closed	-$797K	–	1729
2022 Q4	$621K	Buy	+52,470	New	+$381K	﹤0.01%	1234
2021 Q1	–	Sell	-13,034	Closed	-$678K	–	1601
2020 Q4	$678K	Buy	+13,034	New	+$440K	0.01%	1078

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Capital Fund Management (CFM)'s TGTX Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its TG Therapeutics (TGTX) stake by 39% in Q2 2026, selling an estimated $1.8M and leaving 68,764 shares worth $3.78M. The position accounts for 0.02% of the portfolio, ranked #1072.

Capital Fund Management (CFM) first reported a position in TGTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $6.92M in Q2 2024. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Capital Fund Management (CFM) held 68,764 shares of TG Therapeutics worth $3.78M as of Q2 2026.
Capital Fund Management (CFM) sold 43,920 TG Therapeutics shares in Q2 2026, an estimated $1.8M.
TG Therapeutics made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1072 holding.
Capital Fund Management (CFM) first reported a position in TG Therapeutics in Q4 2020 and has held it in 11 quarters since.
Capital Fund Management (CFM)'s TG Therapeutics position peaked at $6.92M in Q2 2024.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.